Publication: HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy
dc.contributor.author | T. Puthanakit | en_US |
dc.contributor.author | G. Jourdain | en_US |
dc.contributor.author | S. Hongsiriwon | en_US |
dc.contributor.author | P. Suntarattiwong | en_US |
dc.contributor.author | K. Chokephaibulkit | en_US |
dc.contributor.author | V. Sirisanthana | en_US |
dc.contributor.author | P. Kosalaraksa | en_US |
dc.contributor.author | W. Petdachai | en_US |
dc.contributor.author | R. Hansudewechakul | en_US |
dc.contributor.author | U. Siangphoe | en_US |
dc.contributor.author | T. Suwanlerk | en_US |
dc.contributor.author | J. Ananworanich | en_US |
dc.contributor.other | The HIV Netherlands Australia Thailand Research Collaboration | en_US |
dc.contributor.other | Chulalongkorn University | en_US |
dc.contributor.other | Chiang Mai University | en_US |
dc.contributor.other | Regional Hospital | en_US |
dc.contributor.other | Queen Sirikit National Institute of Child Health | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Khon Kaen University | en_US |
dc.contributor.other | Petchburi Hospital | en_US |
dc.contributor.other | Chiang Rai Regional Hospital | en_US |
dc.contributor.other | South East Asia Research Collaboration with Hawaii | en_US |
dc.date.accessioned | 2018-09-24T09:21:02Z | |
dc.date.available | 2018-09-24T09:21:02Z | |
dc.date.issued | 2010-10-01 | en_US |
dc.description.abstract | Objectives: The aim of the study was to assess the prevalence, predictors and patterns of genotypic resistance mutations in children after failure of World Health Organization-recommended initial nonnucleoside reverse transcriptase inhibitor (NNRTI)-based treatment regimens. Methods: We carried out a multicentre retrospective study of genotyping tests performed for all HIV-infected children at eight paediatric centres in Thailand who experienced failure of NNRTI therapy at a time when virological monitoring was not routinely available. Results: One hundred and twenty children were included in the study. Their median age (interquartile range) was 9.1 (6.8-11.0) years, the median duration of their NNRTI regimens was 23.7 (15.7-32.6) months, their median CD4 percentage was 12% (4-20%), and their median plasma HIV RNA at the time of genotype testing was 4.8 (4.3-5.2) log10 HIV-1 RNA copies/mL. The nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations found were as follows: 85% of the children had M184V/I, 23% had at least four thymidine analogue mutations, 12% had the Q151M complex, 5% had K65R, and 1% had the 69 insertion. Ninety-eight per cent of the children had at least one NNRTI resistance mutation, and 48% had etravirine mutation-weighted scores ≥4. CD4 percentage <15% prior to switching regimens [odds ratio (OR) 5.49; 95% confidence interval (CI) 2.02-14.93] and plasma HIV RNA>5 log10 copies/mL (OR 2.46; 95% CI 1.04-5.82) were independent predictors of at least four thymidine analogue mutations, the Q151M complex or the 69 insertion. Conclusions: In settings without routine viral load monitoring, second-line antiretroviral therapy regimens should be designed assuming that clinical or immunological failure is associated with high rates of multi-NRTI resistance and NNRTI resistance, including resistance to etravirine. © 2010 British HIV Association. | en_US |
dc.identifier.citation | HIV Medicine. Vol.11, No.9 (2010), 565-572 | en_US |
dc.identifier.doi | 10.1111/j.1468-1293.2010.00828.x | en_US |
dc.identifier.issn | 14681293 | en_US |
dc.identifier.issn | 14642662 | en_US |
dc.identifier.other | 2-s2.0-77955610006 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/29527 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77955610006&origin=inward | en_US |
dc.subject | Medicine | en_US |
dc.title | HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77955610006&origin=inward | en_US |